Answers are grounded in this paper and cite their sources.
Background: Obesity is associated with chronic inflammation and metabolic disorders, including Type 2 Diabetes Mellitus (T2DM). Biomarkers such as Interleukin-1β (IL-1β), Neutrophil-to-Lymphocyte Ratio (NLR), Mean Platelet Volume (MPV), and Fasting Plasma Glucose (FPG) are commonly used to assess inflammation and metabolic status. Propolis has demonstrated anti-inflammatory effects, however evidence in obese individuals with and without T2DM remains limited. This study evaluated the effects of propolis supplementation on these biomarkers.Materials and methods: A total of 45 obese adults aged <60 years, with and without T2DM, received 400 mg/day of propolis extract for 30 days. Participants receiving anti-inflammatory or steroid therapy, experiencing severe depression or anxiety requiring treatment, or unwilling to participate were excluded. Blood samples were collected to measure IL-1β, NLR, MPV, and FPG. IL-1β was analyzed using ELISA, while NLR, MPV, and FPG were assessed using automated laboratory analyzers. Pre- and post-intervention values were compared using paired statistical tests.Results: Obese individuals with T2DM demonstrated more pronounced changes in Inflammatory and hematological biomarkers than obese individuals without T2DM. In obese with T2DM group, significant reductions were observed in NLR (p=0.003), MPV (p=0.031), and FPG (p=0.046), while IL-1β showed no significant. In obese without T2DM group, MPV decreased significantly, IL-1β and NLR did not change significantly. FPG increased modestly, remained within the normal range.Conclusion: Propolis supplementation improved NLR, MPV and FPG more prominently in obese with T2DM than obese without T2DM, suggesting greater benefits under metabolically dysregulated conditions.
No takes yet. Share an insight, caveat, or question.
Setiawati et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: